<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836355</url>
  </required_header>
  <id_info>
    <org_study_id>08-131</org_study_id>
    <nct_id>NCT00836355</nct_id>
  </id_info>
  <brief_title>Enoxaparin and/or Minocycline in Acute Stroke</brief_title>
  <official_title>Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James N. Kirby Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether enoxaparin, minocycline, or both
      medications in combination may help in recovery from acute stroke.

      Enoxaparin (brand name Lovenox®) is a medication approved for use in humans to prevent and to
      treat blood clots in deep veins in certain specific medical situations. Minocycline (brand
      name Minocin®) is a tetracycline antibiotic approved to treat a number of bacterial
      infections in humans. The investigators are studying these medications in acute human stroke
      because they have each been separately shown to reduce the amount of injured brain tissue in
      rats made to have acute ischemic stroke experimentally. In a human trial comparing
      minocycline with placebo (a sugar pill) acute ischemic stroke patients who took minocycline
      had better recovery after 1 week, 1 month and 3 months than patients who took placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enoxaparin is a low molecular weight heparin (average molecular weight 4,500 daltons, vs.
      12,000 to 15,000 daltons for unfractionated heparin) administered subcutaneously and
      intravenously. It is a marketed drug FDA-approved in various clinical situations for: the
      prevention and treatment of deep vein thrombosis; and in the treatment of acute myocardial
      infarction. Minocycline is an orally administered antibiotic of the tetracycline class. It is
      a marketed drug FDA-approved for the treatment of various bacterial and rickettsial
      infections. Both medications have been found to be neuroprotective in experimental stroke
      models. Minocycline has shown promise in a human acute stroke study.

      This study is designed to investigate two logistically simple treatment regimens, singly or
      in combination, employing these medications for acute ischemic stroke:

        1. pulsed intravenous (iv) administration of enoxaparin initiated within 6 hours and
           completed by 24 hours after stroke onset; and

        2. oral minocycline treatment once daily for five days.

      The goal of treatment is neuroprotection: the limitation of the loss of brain tissue that
      follows ischemic stroke.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Too few acute stroke patients available to meet enrollment requirements.
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Indices of Salvaged Ischemic Penumbra and of Final Infarct Volume Based on Quantitative Volumetric Analyses of Pre- and Post-treatment Perfusion-weighted and Diffusion-weighted Brain MR Imaging</measure>
    <time_frame>Within approximately 7 days of stroke onset</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale Scores</measure>
    <time_frame>Baseline and after approximately one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>Baseline, and approximately one week and 3 months later</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline 200 mg orally once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin and minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>2 (or 3) intravenous doses, the first on study entry, the last 24 hours later</description>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_label>Enoxaparin and minocycline</arm_group_label>
    <other_name>Lovenox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>200 mg orally once daily for 5 days</description>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_label>Enoxaparin and minocycline</arm_group_label>
    <other_name>Minocin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        There are two Study Sections: A and B

        Study Section A Inclusion Criteria:

          1. acute ischemic stroke in an adult in-patient who can complete screening and begin
             study treatment within 6 hours of stroke onset (onset time defined as the last time
             the patient was known to be at his/her usual level of functioning)

          2. patient not a candidate for rTPA treatment because treatment cannot be started within
             the required 3 hours after stroke onset, or because rTPA treatment is refused.

        Study Section A Exclusion Criteria:

          1. intracranial hemorrhage;

          2. subfalcine, transtentorial, or foramen magnum herniation on CT or MRI scan of the
             brain;

          3. history of hypersensitivity or intolerance to or toxicity from enoxaparin, other
             heparinoids, heparin, minocycline, or other tetracyclines;

          4. weight 125lbs or less;

          5. active bleeding;

          6. thrombolytic treatment or major surgery in the previous 24 hours;

          7. anticipated need for treatment with coumarin, or a low-molecular weight heparin other
             than enoxaparin, or unfractionated heparin before 36 hours after stroke onset (but see
             deep venous thrombosis prophylaxis, below);

          8. INR above the normal range;

          9. known coagulopathy;

         10. platelet count &lt;100,000/mm3 (if the count drops below 100,000 while on enoxaparin, the
             medication will be stopped)

         11. pregnancy or lactation;

         12. undergoing dialysis; severe renal impairment (creatinine clearance known or estimated
             to be &lt;30ml/min);

         13. mean arterial BP (taken to be 1/3 of the difference in mm Hg between diastolic BP and
             systolic BP, added to the diastolic BP) of 130 mm Hg or greater; (if the mean arterial
             BP is 130 mm Hg or greater but can be reduced by treatment to &lt; 130 mm Hg, with
             systolic BP in the 150 169 mm Hg range, the patient may be entered).

        Patients in Study Section A will be randomly assigned to one of the four treatment arms:
        enoxaparin, minocycline, enoxaparin and minocycline, or no intervention.

        Study Section B Inclusion Criteria:

          1. acute ischemic stroke in an adult in-patient who can complete screening and begin
             study treatment within 24 hours of stroke onset (onset time defined as the last time
             the patient was known to be at his/her usual level of functioning;)

          2. patient does not qualify for, or declines to participate in, Study Section A.

        Study Section B Exclusion Criteria:

          1. acute primary intracranial hemorrhage;

          2. subfalcine, transtentorial, or foramen magnum herniation on CT or MRI scan of the
             brain;

          3. pregnancy or lactation.

        Patients in Study Section B will be randomly assigned to one of TWO treatment arms:
        minocycline, or no intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saran Jonas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology; New York University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giacinto Grieco, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Neurology; New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007 Oct 2;69(14):1404-10.</citation>
    <PMID>17909152</PMID>
  </reference>
  <reference>
    <citation>Mary V, Wahl F, Uzan A, Stutzmann JM. Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. Stroke. 2001 Apr;32(4):993-9.</citation>
    <PMID>11283402</PMID>
  </reference>
  <reference>
    <citation>Quartermain D, Li Y, Jonas S. Enoxaparin, a low molecular weight heparin decreases infarct size and improves sensorimotor function in a rat model of focal cerebral ischemia. Neurosci Lett. 2000 Jul 14;288(2):155-8.</citation>
    <PMID>10876084</PMID>
  </reference>
  <reference>
    <citation>Quartermain D, Li YS, Jonas S. The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia. Cerebrovasc Dis. 2003;16(4):346-55.</citation>
    <PMID>13130175</PMID>
  </reference>
  <reference>
    <citation>Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7.</citation>
    <PMID>15109399</PMID>
  </reference>
  <reference>
    <citation>Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13496-500.</citation>
    <PMID>10557349</PMID>
  </reference>
  <reference>
    <citation>Liu Z, Fan Y, Won SJ, Neumann M, Hu D, Zhou L, Weinstein PR, Liu J. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke. 2007 Jan;38(1):146-52. Epub 2006 Nov 22.</citation>
    <PMID>17122429</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>February 29, 2016</results_first_submitted>
  <results_first_submitted_qc>March 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2016</results_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>enoxaparin</keyword>
  <keyword>minocycline</keyword>
  <keyword>NIH stroke scale</keyword>
  <keyword>modified Rankin scale</keyword>
  <keyword>neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enoxaparin</title>
          <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later</description>
        </group>
        <group group_id="P2">
          <title>Minocycline</title>
          <description>Minocycline 200 mg orally once daily for 5 days
Minocycline: 200 mg orally once daily for 5 days</description>
        </group>
        <group group_id="P3">
          <title>Enoxaparin and Minocycline</title>
          <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
Minocycline: 200 mg orally once daily for 5 days</description>
        </group>
        <group group_id="P4">
          <title>Control</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enoxaparin</title>
          <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later</description>
        </group>
        <group group_id="B2">
          <title>Minocycline</title>
          <description>Minocycline 200 mg orally once daily for 5 days
Minocycline: 200 mg orally once daily for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Enoxaparin and Minocycline</title>
          <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
Minocycline: 200 mg orally once daily for 5 days</description>
        </group>
        <group group_id="B4">
          <title>Control</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Indices of Salvaged Ischemic Penumbra and of Final Infarct Volume Based on Quantitative Volumetric Analyses of Pre- and Post-treatment Perfusion-weighted and Diffusion-weighted Brain MR Imaging</title>
        <time_frame>Within approximately 7 days of stroke onset</time_frame>
        <population>Although all participants completed the study, none of them had the necessary MRIs performed to gather outcome measure data. The study was closed once it was determined that logistically, it was not possible to complete the study at that point in time.</population>
        <group_list>
          <group group_id="O1">
            <title>Enoxaparin</title>
            <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later</description>
          </group>
          <group group_id="O2">
            <title>Minocycline</title>
            <description>Minocycline 200 mg orally once daily for 5 days
Minocycline: 200 mg orally once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin and Minocycline</title>
            <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
Minocycline: 200 mg orally once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Indices of Salvaged Ischemic Penumbra and of Final Infarct Volume Based on Quantitative Volumetric Analyses of Pre- and Post-treatment Perfusion-weighted and Diffusion-weighted Brain MR Imaging</title>
          <population>Although all participants completed the study, none of them had the necessary MRIs performed to gather outcome measure data. The study was closed once it was determined that logistically, it was not possible to complete the study at that point in time.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NIH Stroke Scale Scores</title>
        <time_frame>Baseline and after approximately one week</time_frame>
        <population>This trial was terminated early because of logistical challenges in data collection. No outcome measures data was able to be collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Enoxaparin</title>
            <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later</description>
          </group>
          <group group_id="O2">
            <title>Minocycline</title>
            <description>Minocycline 200 mg orally once daily for 5 days
Minocycline: 200 mg orally once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin and Minocycline</title>
            <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
Minocycline: 200 mg orally once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>NIH Stroke Scale Scores</title>
          <population>This trial was terminated early because of logistical challenges in data collection. No outcome measures data was able to be collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Rankin Scale Score</title>
        <time_frame>Baseline, and approximately one week and 3 months later</time_frame>
        <population>This trial was terminated early because of logistical challenges in data collection. No outcome measures data was able to be collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Enoxaparin</title>
            <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later</description>
          </group>
          <group group_id="O2">
            <title>Minocycline</title>
            <description>Minocycline 200 mg orally once daily for 5 days
Minocycline: 200 mg orally once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin and Minocycline</title>
            <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
Minocycline: 200 mg orally once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale Score</title>
          <population>This trial was terminated early because of logistical challenges in data collection. No outcome measures data was able to be collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enoxaparin</title>
          <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later</description>
        </group>
        <group group_id="E2">
          <title>Minocycline</title>
          <description>Minocycline 200 mg orally once daily for 5 days
Minocycline: 200 mg orally once daily for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Enoxaparin and Minocycline</title>
          <description>Enoxaparin: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
Minocycline: 200 mg orally once daily for 5 days</description>
        </group>
        <group group_id="E4">
          <title>Control</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was terminated early because of logistical challenges in data collection. No outcome measures data was able to be collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Saran Jonas</name_or_title>
      <organization>New York University Langone Medical Center</organization>
      <phone>212 263 7591</phone>
      <email>Saran.Jonas@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

